0001209191-22-042211.txt : 20220714
0001209191-22-042211.hdr.sgml : 20220714
20220714213350
ACCESSION NUMBER: 0001209191-22-042211
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220712
FILED AS OF DATE: 20220714
DATE AS OF CHANGE: 20220714
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Helash Kevin
CENTRAL INDEX KEY: 0001818849
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36030
FILM NUMBER: 221084161
MAIL ADDRESS:
STREET 1: C/O MARRONE BIO INNOVATIONS, INC.
STREET 2: 1540 DREW AVENUE
CITY: DAVIS
STATE: CA
ZIP: 95618
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MARRONE BIO INNOVATIONS INC
CENTRAL INDEX KEY: 0001441693
STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE CHEMICALS [2870]
IRS NUMBER: 205137161
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7780-420 BRIER CREEK PARKWAY
STREET 2: RALEIGH
CITY: RALEIGH
STATE: NC
ZIP: 27617
BUSINESS PHONE: 530-750-2800
MAIL ADDRESS:
STREET 1: 7780-420 BRIER CREEK PARKWAY
STREET 2: RALEIGH
CITY: RALEIGH
STATE: NC
ZIP: 27617
FORMER COMPANY:
FORMER CONFORMED NAME: MARRONE ORGANICS INNOVATIONS INC
DATE OF NAME CHANGE: 20080801
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-07-12
1
0001441693
MARRONE BIO INNOVATIONS INC
MBII
0001818849
Helash Kevin
C/O MARRONE BIO INNOVATIONS, INC.
7780-420 BRIER CREEK PARKWAY
RALEIGH
NC
27617-7882
1
1
0
0
Chief Executive Officer
Common Stock
2022-07-12
4
D
0
241568
0.00
D
0
D
Stock Option (Right to Buy)
0.6321
2022-07-12
4
D
0
417273
0.00
D
2032-02-07
Common Stock
417273
0
D
Stock Option (Right to Buy)
1.16
2022-07-12
4
D
0
2450000
0.00
D
2030-08-04
Common Stock
2450000
0
D
Certain unvested restricted stock units became vested and all vested restricted stock units were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement") in exchange for 14,482 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger, and 6,776 restricted stock units (each restricted stock unit represents a contingent right to receive one Ordinary Share of BIOX).
This option, which provided for vesting in equal monthly installments over three years, beginning on March 7, 2022, was assumed by BIOX with respect to 237,611 shares and replaced with an option to purchase 15,810 Ordinary Shares of BIOX for $7.16 per share. The remainder of the option was cancelled in the Merger in exchange for 9,042 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.
This option, which provided (1) with respect to 225,000 options, for vesting of 25% of the total shares subject to the option on the first anniversary of the vesting commencement date of August 3, 2020, with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months; (2) with respect to 2,000,000 options, for vesting if/when performance milestone is attained; and (3) with respect to 225,000 options, for vesting over a period of four years as measured from the vesting commencement date of August 4, 2020, on a pro-rata basis equally each month, was assumed by BIOX in the Merger and replaced with an option to purchase 215,600 Ordinary Shares of BIOX for $13.18 per share.
/s/ Linda V. Moore, as attorney in fact
2022-07-14